stockrowCompugen Ltd.
CGENCompugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.
- Revenue
- +107.0%
- EPS
- +12.5%
- Free cash flow
- −155.4%
Quarter to June 2026, against a year earlier
Follow CGEN
Alert me
Compugen Ltd. (CGEN) EV/Sales
As of 6 November 2026, Compugen Ltd. (CGEN) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −2.5× (September 2022) to 308× (May 2017); the current reading is higher than 13% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 1.2× | (84.90%) |
| FY2023 | 8.0× | — |
| FY2022 | −1.4× | — |
| FY2021 | 15.5× | (63.53%) |
| FY2020 | 42.4× | 919.01% |
| FY2018 | 4.2× | (98.50%) |
| FY2016 | 278× | 969.62% |
| FY2015 | 26.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 14.10% |
| Mar 2026 | 0.9× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 7.4× | 691.51% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| UPB Upstream Bio, Inc. compare | −26.9× |
| RNA Atrium Therapeutics, Inc. compare | −4.3× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −2.3× |
| KROS Keros Therapeutics, Inc. compare | −1.3× |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| CGEN Compugen Ltd. | 0.8× |
| PRQR ProQR Therapeutics N.V. compare | 1.1× |
| TRDA Entrada Therapeutics, Inc. compare | 3.6× |
| ACOG Alpha Cognition Inc. compare | 9.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)